CA2961748A1 - Oncolytic tumor viruses and methods of use - Google Patents

Oncolytic tumor viruses and methods of use Download PDF

Info

Publication number: CA2961748A1
Authority: CA; Canada
Prior art keywords: protein; adenovirus; modified; recombinant adenovirus; seq
Prior art date: 2014-09-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA2961748A

Other languages

English (en)

French (fr)

Inventor

Clodagh O'shea

Shigeki MIYAKE-STONER

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Salk Institute for Biological Studies

Original Assignee

Salk Institute for Biological Studies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-24

Filing date

2015-09-23

Publication date

2016-03-31

2015-09-23 Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies

2016-03-31 Publication of CA2961748A1 publication Critical patent/CA2961748A1/en

Status Pending legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims description 163
238000000034 method Methods 0.000 title claims description 62
241000700605 Viruses Species 0.000 title abstract description 159
230000000174 oncolytic effect Effects 0.000 title description 39
241000701161 unidentified adenovirus Species 0.000 claims abstract description 375
210000004027 cell Anatomy 0.000 claims abstract description 267
108090000623 proteins and genes Proteins 0.000 claims abstract description 239
102000004169 proteins and genes Human genes 0.000 claims abstract description 210
230000035772 mutation Effects 0.000 claims abstract description 95
230000027455 binding Effects 0.000 claims abstract description 65
210000004185 liver Anatomy 0.000 claims abstract description 65
210000004881 tumor cell Anatomy 0.000 claims abstract description 48
101710199711 Early E1A protein Proteins 0.000 claims abstract 21
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 130
229960002930 sirolimus Drugs 0.000 claims description 126
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 121
239000000835 fiber Substances 0.000 claims description 84
238000006467 substitution reaction Methods 0.000 claims description 80
238000012217 deletion Methods 0.000 claims description 76
230000037430 deletion Effects 0.000 claims description 76
201000011510 cancer Diseases 0.000 claims description 54
230000010076 replication Effects 0.000 claims description 51
239000000203 mixture Substances 0.000 claims description 49
150000007523 nucleic acids Chemical class 0.000 claims description 48
239000013598 vector Substances 0.000 claims description 44
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical class CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 38
230000007547 defect Effects 0.000 claims description 38
102000039446 nucleic acids Human genes 0.000 claims description 36
108020004707 nucleic acids Proteins 0.000 claims description 36
230000008685 targeting Effects 0.000 claims description 32
101710145505 Fiber protein Proteins 0.000 claims description 30
239000002679 microRNA Substances 0.000 claims description 30
239000002773 nucleotide Substances 0.000 claims description 30
125000003729 nucleotide group Chemical group 0.000 claims description 30
108700011259 MicroRNAs Proteins 0.000 claims description 29
230000037361 pathway Effects 0.000 claims description 25
239000003814 drug Substances 0.000 claims description 22
239000005089 Luciferase Substances 0.000 claims description 18
101710094396 Hexon protein Proteins 0.000 claims description 17
239000003446 ligand Substances 0.000 claims description 16
229940124597 therapeutic agent Drugs 0.000 claims description 15
108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 14
102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 14
206010006187 Breast cancer Diseases 0.000 claims description 13
108010003723 Single-Domain Antibodies Proteins 0.000 claims description 13
208000026310 Breast neoplasm Diseases 0.000 claims description 12
108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 11
230000002401 inhibitory effect Effects 0.000 claims description 10
108020005345 3' Untranslated Regions Proteins 0.000 claims description 9
108091007780 MiR-122 Proteins 0.000 claims description 9
238000001727 in vivo Methods 0.000 claims description 9
CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical class ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims description 8
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
230000001506 immunosuppresive effect Effects 0.000 claims description 7
208000032839 leukemia Diseases 0.000 claims description 7
108091051828 miR-122 stem-loop Proteins 0.000 claims description 7
206010061309 Neoplasm progression Diseases 0.000 claims description 6
210000000481 breast Anatomy 0.000 claims description 6
239000003112 inhibitor Substances 0.000 claims description 6
230000005751 tumor progression Effects 0.000 claims description 6
210000004072 lung Anatomy 0.000 claims description 5
208000020816 lung neoplasm Diseases 0.000 claims description 5
210000002307 prostate Anatomy 0.000 claims description 5
210000001685 thyroid gland Anatomy 0.000 claims description 5
102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 4
108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 4
206010062016 Immunosuppression Diseases 0.000 claims description 4
208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
230000003831 deregulation Effects 0.000 claims description 4
238000000338 in vitro Methods 0.000 claims description 4
208000014018 liver neoplasm Diseases 0.000 claims description 4
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 3
102000006495 integrins Human genes 0.000 claims description 3
108010044426 integrins Proteins 0.000 claims description 3
230000010304 tumor cell viability Effects 0.000 claims description 3
206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
208000037841 lung tumor Diseases 0.000 claims description 2
208000023958 prostate neoplasm Diseases 0.000 claims description 2
208000013076 thyroid tumor Diseases 0.000 claims description 2
101710173835 Penton protein Proteins 0.000 claims 2
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
230000009261 transgenic effect Effects 0.000 claims 1
238000012986 modification Methods 0.000 abstract description 53
230000004048 modification Effects 0.000 abstract description 52
238000011282 treatment Methods 0.000 abstract description 36
230000003472 neutralizing effect Effects 0.000 abstract description 16
230000029812 viral genome replication Effects 0.000 abstract description 11
230000002074 deregulated effect Effects 0.000 abstract description 7
230000003612 virological effect Effects 0.000 abstract description 7
108010077850 Nuclear Localization Signals Proteins 0.000 abstract description 4
108050002653 Retinoblastoma protein Proteins 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 157
241001135569 Human adenovirus 5 Species 0.000 description 120
208000015181 infectious disease Diseases 0.000 description 99
230000014509 gene expression Effects 0.000 description 65
241000894007 species Species 0.000 description 50
125000003275 alpha amino acid group Chemical group 0.000 description 48
230000000694 effects Effects 0.000 description 32
241000699670 Mus sp. Species 0.000 description 29
108090000765 processed proteins & peptides Proteins 0.000 description 27
239000007924 injection Substances 0.000 description 26
238000002347 injection Methods 0.000 description 26
102000001301 EGF receptor Human genes 0.000 description 25
235000001014 amino acid Nutrition 0.000 description 25
230000001413 cellular effect Effects 0.000 description 25
108060006698 EGF receptor Proteins 0.000 description 24
150000001413 amino acids Chemical class 0.000 description 24
210000000234 capsid Anatomy 0.000 description 24
239000003795 chemical substances by application Substances 0.000 description 20
108020004414 DNA Proteins 0.000 description 19
244000309459 oncolytic virus Species 0.000 description 19
101710155188 Hexon-interlacing protein Proteins 0.000 description 18
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 18
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 18
230000003833 cell viability Effects 0.000 description 18
108020001507 fusion proteins Proteins 0.000 description 18
102000037865 fusion proteins Human genes 0.000 description 18
239000002245 particle Substances 0.000 description 18
230000002147 killing effect Effects 0.000 description 17
208000005017 glioblastoma Diseases 0.000 description 16
238000003119 immunoblot Methods 0.000 description 16
238000003780 insertion Methods 0.000 description 16
230000037431 insertion Effects 0.000 description 16
102000004196 processed proteins & peptides Human genes 0.000 description 16
238000013207 serial dilution Methods 0.000 description 16
239000003981 vehicle Substances 0.000 description 16
102100033254 Tumor suppressor ARF Human genes 0.000 description 15
238000003556 assay Methods 0.000 description 15
230000001419 dependent effect Effects 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
-1 for example Chemical group 0.000 description 15
230000002601 intratumoral effect Effects 0.000 description 15
229920001184 polypeptide Polymers 0.000 description 15
JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 15
201000010099 disease Diseases 0.000 description 14
230000003993 interaction Effects 0.000 description 14
238000007912 intraperitoneal administration Methods 0.000 description 14
230000002503 metabolic effect Effects 0.000 description 14
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 14
108060001084 Luciferase Proteins 0.000 description 13
238000009472 formulation Methods 0.000 description 13
230000002458 infectious effect Effects 0.000 description 13
239000000047 product Substances 0.000 description 13
230000004543 DNA replication Effects 0.000 description 12
230000022534 cell killing Effects 0.000 description 12
230000003247 decreasing effect Effects 0.000 description 12
230000002950 deficient Effects 0.000 description 12
230000001771 impaired effect Effects 0.000 description 12
239000013612 plasmid Substances 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
230000007423 decrease Effects 0.000 description 11
230000001939 inductive effect Effects 0.000 description 11
238000007920 subcutaneous administration Methods 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
102000016736 Cyclin Human genes 0.000 description 10
108050006400 Cyclin Proteins 0.000 description 10
241000701168 Murine adenovirus 1 Species 0.000 description 10
101710172711 Structural protein Proteins 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
239000012634 fragment Substances 0.000 description 10
230000000670 limiting effect Effects 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
102000002554 Cyclin A Human genes 0.000 description 9
108010068192 Cyclin A Proteins 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 9
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 9
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 9
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 9
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 9
238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
230000006870 function Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
238000013518 transcription Methods 0.000 description 9
108010035601 Coxsackie and Adenovirus Receptor Like Membrane Protein Proteins 0.000 description 8
102000008198 Coxsackie and Adenovirus Receptor Like Membrane Protein Human genes 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
241000598171 Human adenovirus sp. Species 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 8
230000002062 proliferating effect Effects 0.000 description 8
102000002427 Cyclin B Human genes 0.000 description 7
108010068150 Cyclin B Proteins 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 7
239000000969 carrier Substances 0.000 description 7
230000004927 fusion Effects 0.000 description 7
229910052700 potassium Inorganic materials 0.000 description 7
230000006798 recombination Effects 0.000 description 7
238000005215 recombination Methods 0.000 description 7
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 6
108090000565 Capsid Proteins Proteins 0.000 description 6
102100023321 Ceruloplasmin Human genes 0.000 description 6
108091026890 Coding region Proteins 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
201000000582 Retinoblastoma Diseases 0.000 description 6
230000018199 S phase Effects 0.000 description 6
230000037396 body weight Effects 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
239000013592 cell lysate Substances 0.000 description 6
238000003570 cell viability assay Methods 0.000 description 6
239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 6
229940127089 cytotoxic agent Drugs 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
101100161875 Arabidopsis thaliana ACR2 gene Proteins 0.000 description 5
101100495264 Arabidopsis thaliana CDC25 gene Proteins 0.000 description 5
206010055113 Breast cancer metastatic Diseases 0.000 description 5
108091007914 CDKs Proteins 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
206010025323 Lymphomas Diseases 0.000 description 5
102100039120 Retinoblastoma-like protein 1 Human genes 0.000 description 5
108050002592 Retinoblastoma-like protein 1 Proteins 0.000 description 5
101100380266 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ARR2 gene Proteins 0.000 description 5
206010039491 Sarcoma Diseases 0.000 description 5
101150004068 acrB gene Proteins 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
210000001552 airway epithelial cell Anatomy 0.000 description 5
210000001130 astrocyte Anatomy 0.000 description 5
230000022131 cell cycle Effects 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
108091070501 miRNA Proteins 0.000 description 5
230000026731 phosphorylation Effects 0.000 description 5
238000006366 phosphorylation reaction Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
238000010186 staining Methods 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
101150066038 E4 gene Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
206010018338 Glioma Diseases 0.000 description 4
206010027476 Metastases Diseases 0.000 description 4
102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 4
108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 4
108010067390 Viral Proteins Proteins 0.000 description 4
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
230000002238 attenuated effect Effects 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
206010073071 hepatocellular carcinoma Diseases 0.000 description 4
239000007788 liquid Substances 0.000 description 4
201000005249 lung adenocarcinoma Diseases 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000003362 replicative effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
238000010361 transduction Methods 0.000 description 4
230000026683 transduction Effects 0.000 description 4
210000003556 vascular endothelial cell Anatomy 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
208000010370 Adenoviridae Infections Diseases 0.000 description 3
206010060931 Adenovirus infection Diseases 0.000 description 3
206010003571 Astrocytoma Diseases 0.000 description 3
208000003174 Brain Neoplasms Diseases 0.000 description 3
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
208000006332 Choriocarcinoma Diseases 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
102000003910 Cyclin D Human genes 0.000 description 3
108090000259 Cyclin D Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
108010093502 E2F Transcription Factors Proteins 0.000 description 3
102000001388 E2F Transcription Factors Human genes 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 3
101000895882 Homo sapiens Transcription factor E2F4 Proteins 0.000 description 3
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
206010029260 Neuroblastoma Diseases 0.000 description 3
108091005461 Nucleic proteins Chemical group 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
108700025701 Retinoblastoma Genes Proteins 0.000 description 3
108091006629 SLC13A2 Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
102100021783 Transcription factor E2F4 Human genes 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000007792 addition Methods 0.000 description 3
208000011589 adenoviridae infectious disease Diseases 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000000833 heterodimer Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
125000001165 hydrophobic group Chemical group 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
239000006166 lysate Substances 0.000 description 3
230000002101 lytic effect Effects 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
210000004882 non-tumor cell Anatomy 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 3
230000000737 periodic effect Effects 0.000 description 3
238000012877 positron emission topography Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000002271 resection Methods 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
230000005945 translocation Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
OOVTUOCTLAERQD-OJMBIDBESA-N 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride Chemical compound Cl.OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O OOVTUOCTLAERQD-OJMBIDBESA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
208000005243 Chondrosarcoma Diseases 0.000 description 2
229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
102000005707 Desmoglein 2 Human genes 0.000 description 2
108010045583 Desmoglein 2 Proteins 0.000 description 2
108010014173 Factor X Proteins 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000018142 Leiomyosarcoma Diseases 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
206010024305 Leukaemia monocytic Diseases 0.000 description 2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
208000000172 Medulloblastoma Diseases 0.000 description 2
102100039373 Membrane cofactor protein Human genes 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
238000002944 PCR assay Methods 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
208000007452 Plasmacytoma Diseases 0.000 description 2
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
102100038042 Retinoblastoma-associated protein Human genes 0.000 description 2
101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
229950010817 alvocidib Drugs 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003263 anti-adenoviral effect Effects 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
238000002869 basic local alignment search tool Methods 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
229960002092 busulfan Drugs 0.000 description 2
235000013877 carbamide Nutrition 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
PWUOOJVYZQILBG-UHFFFAOYSA-N fascaplysine Chemical compound [Cl-].C1=CC=C2C3=CC=[N+]4C5=CC=CC=C5C(=O)C4=C3NC2=C1 PWUOOJVYZQILBG-UHFFFAOYSA-N 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
230000030279 gene silencing Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
238000011532 immunohistochemical staining Methods 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000011021 lapis lazuli Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
206010024627 liposarcoma Diseases 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
229940124302 mTOR inhibitor Drugs 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
229960004961 mechlorethamine Drugs 0.000 description 2
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
210000002418 meninge Anatomy 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
201000006894 monocytic leukemia Diseases 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
208000025189 neoplasm of testis Diseases 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
208000007538 neurilemmoma Diseases 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000030648 nucleus localization Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
229960004390 palbociclib Drugs 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229960003171 plicamycin Drugs 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
235000013930 proline Nutrition 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000002639 sodium chloride Nutrition 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
QNUKRWAIZMBVCU-WCIBSUBMSA-N su9516 Chemical compound C12=CC(OC)=CC=C2NC(=O)\C1=C/C1=CN=CN1 QNUKRWAIZMBVCU-WCIBSUBMSA-N 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012385 systemic delivery Methods 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
230000006648 viral gene expression Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000001262 western blot Methods 0.000 description 2
BTIHMVBBUGXLCJ-HNNXBMFYSA-N (2s)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-HNNXBMFYSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
MRPGRAKIAJJGMM-OCCSQVGLSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC(=CC=1)C(F)(F)F)Cl)=CC2=O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 1
HFPLHASLIOXVGS-UHFFFAOYSA-N 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione Chemical compound S1C(C)=NC(C2=O)=C1C(=O)C=C2NC1=CC=C(C)C=C1 HFPLHASLIOXVGS-UHFFFAOYSA-N 0.000 description 1
IGRZXNLKVUEFDM-UHFFFAOYSA-N 2-phenyl-N-(5-propan-2-yl-2-thiazolyl)acetamide Chemical compound S1C(C(C)C)=CN=C1NC(=O)CC1=CC=CC=C1 IGRZXNLKVUEFDM-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
WJRRGYBTGDJBFX-UHFFFAOYSA-N 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WJRRGYBTGDJBFX-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
206010001258 Adenoviral infections Diseases 0.000 description 1
108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
239000012099 Alexa Fluor family Substances 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101100172201 Arabidopsis thaliana ELP2 gene Proteins 0.000 description 1
101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
101710082924 Atypical protein kinase C Proteins 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
229940123587 Cell cycle inhibitor Drugs 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
ZGERHCJBLPQPGV-ACZMJKKPSA-N Cys-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N ZGERHCJBLPQPGV-ACZMJKKPSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
101710155964 Diuretic hormone 1 Proteins 0.000 description 1
101710114676 E1B 55 kDa protein Proteins 0.000 description 1
101150005585 E3 gene Proteins 0.000 description 1
101150039808 Egfr gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
208000002519 Epithelioid Leiomyoma Diseases 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
108091092566 Extrachromosomal DNA Proteins 0.000 description 1
102220566738 FRAS1-related extracellular matrix protein 1_E93A_mutation Human genes 0.000 description 1
108010039471 Fas Ligand Protein Proteins 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
208000000527 Germinoma Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
FTIJVMLAGRAYMJ-MNXVOIDGSA-N Gln-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(N)=O FTIJVMLAGRAYMJ-MNXVOIDGSA-N 0.000 description 1
CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
206010073069 Hepatic cancer Diseases 0.000 description 1
RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
241000701149 Human adenovirus 1 Species 0.000 description 1
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
RENBRDSDKPSRIH-HJWJTTGWSA-N Ile-Phe-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O RENBRDSDKPSRIH-HJWJTTGWSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
102220580968 Induced myeloid leukemia cell differentiation protein Mcl-1_F47Y_mutation Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000007054 Medullary Carcinoma Diseases 0.000 description 1
208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
208000005890 Neuroma Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000038030 PI3Ks Human genes 0.000 description 1
108091007960 PI3Ks Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
206010033701 Papillary thyroid cancer Diseases 0.000 description 1
102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
101800001494 Protease 2A Proteins 0.000 description 1
101800001066 Protein 2A Proteins 0.000 description 1
101710196756 Protein 33K Proteins 0.000 description 1
101100278874 Prunus persica GNS1 gene Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
101150040459 RAS gene Proteins 0.000 description 1
101150076031 RAS1 gene Proteins 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 1
108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 1
101100501248 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ELO2 gene Proteins 0.000 description 1
101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000187391 Streptomyces hygroscopicus Species 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
208000017733 acquired polycythemia vera Diseases 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
210000005058 airway cell Anatomy 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
229940098174 alkeran Drugs 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
108010062796 arginyllysine Proteins 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
229940108502 bicnu Drugs 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
201000007180 bile duct carcinoma Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
238000013276 bronchoscopy Methods 0.000 description 1
229950009494 bropirimine Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
NGOLMNWQNHWEKU-DEOSSOPVSA-N butyrolactone I Chemical compound C([C@@]1(C(=O)OC)C(=C(O)C(=O)O1)C=1C=CC(O)=CC=1)C1=CC=C(O)C(CC=C(C)C)=C1 NGOLMNWQNHWEKU-DEOSSOPVSA-N 0.000 description 1
FQYAPAZNUPTQLD-DEOSSOPVSA-N butyrolactone I Natural products COC1=C(c2ccc(O)cc2)[C@](Cc3ccc(O)c(CC=C(C)C)c3)(OC1=O)C(=O)O FQYAPAZNUPTQLD-DEOSSOPVSA-N 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
229960005084 calcitriol Drugs 0.000 description 1
235000020964 calcitriol Nutrition 0.000 description 1
239000011612 calcitriol Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229940088954 camptosar Drugs 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
101150102092 ccdB gene Proteins 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000024207 chronic leukemia Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000005860 defense response to virus Effects 0.000 description 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000013461 design Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
230000002616 endonucleolytic effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000001973 epigenetic effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011347 external beam therapy Methods 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
210000005002 female reproductive tract Anatomy 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
229960001751 fluoxymesterone Drugs 0.000 description 1
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
102000035175 foldases Human genes 0.000 description 1
108091005749 foldases Proteins 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
238000010362 genome editing Methods 0.000 description 1
201000003115 germ cell cancer Diseases 0.000 description 1
208000003884 gestational trophoblastic disease Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000025750 heavy chain disease Diseases 0.000 description 1
201000002222 hemangioblastoma Diseases 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
208000013210 hematogenous Diseases 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000009033 hematopoietic malignancy Effects 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
201000000284 histiocytoma Diseases 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229940088013 hycamtin Drugs 0.000 description 1
229940096120 hydrea Drugs 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
QPCBNXNDVYOBIP-WHFBIAKZSA-N hymenialdisine Chemical compound NC1=NC(=O)C([C@@H]2[C@@H]3C=C(Br)N=C3C(=O)NCC2)=N1 QPCBNXNDVYOBIP-WHFBIAKZSA-N 0.000 description 1
ATBAETXFFCOZOY-UHFFFAOYSA-N hymenialdisine Natural products N1C(N)=NC(=O)C1=C1C(C=C(Br)N2)=C2C(=O)NCC1 ATBAETXFFCOZOY-UHFFFAOYSA-N 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
210000003026 hypopharynx Anatomy 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
229960002411 imatinib Drugs 0.000 description 1
YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 1
229950009881 indisulam Drugs 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
239000012444 intercalating antibiotic Substances 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
229950003188 isovaleryl diethylamide Drugs 0.000 description 1
QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
201000002250 liver carcinoma Diseases 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000004777 loss-of-function mutation Effects 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
210000005001 male reproductive tract Anatomy 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
238000001466 metabolic labeling Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Chemical class 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
208000037843 metastatic solid tumor Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical group C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
108091086416 miR-192 stem-loop Proteins 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
201000004058 mixed glioma Diseases 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
201000005987 myeloid sarcoma Diseases 0.000 description 1
208000001611 myxosarcoma Diseases 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229940086322 navelbine Drugs 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
244000309711 non-enveloped viruses Species 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000004019 papillary adenocarcinoma Diseases 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
238000009521 phase II clinical trial Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
125000000405 phenylalanyl group Chemical group 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
201000004123 pineal gland cancer Diseases 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
208000037244 polycythemia vera Diseases 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
210000004777 protein coat Anatomy 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
PMXCMJLOPOFPBT-HNNXBMFYSA-N purvalanol A Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PMXCMJLOPOFPBT-HNNXBMFYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
230000033300 receptor internalization Effects 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
208000020615 rectal carcinoma Diseases 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
102220036870 rs587780094 Human genes 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
229950000055 seliciclib Drugs 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
229960003440 semustine Drugs 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000009987 spinning Methods 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
201000010965 sweat gland carcinoma Diseases 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
108010044292 tryptophyltyrosine Proteins 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
208000013706 tumor of meninges Diseases 0.000 description 1
208000025421 tumor of uterus Diseases 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
210000003741 urothelium Anatomy 0.000 description 1
208000024719 uterine cervix neoplasm Diseases 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
230000035899 viability Effects 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
230000007442 viral DNA synthesis Effects 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940053867 xeloda Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Oncology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2961748A 2014-09-24 2015-09-23 Oncolytic tumor viruses and methods of use Pending CA2961748A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462054724P	2014-09-24	2014-09-24
US62/054,724		2014-09-24
PCT/US2015/051745 WO2016049201A1 (en)	2014-09-24	2015-09-23	Oncolytic tumor viruses and methods of use

Publications (1)

Publication Number	Publication Date
CA2961748A1 true CA2961748A1 (en)	2016-03-31

Family

ID=55581955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2961748A Pending CA2961748A1 (en)	2014-09-24	2015-09-23	Oncolytic tumor viruses and methods of use

Country Status (11)

Country	Link
US (1)	US20170202893A1 (ja)
EP (2)	EP3198009B1 (ja)
JP (3)	JP6764859B2 (ja)
KR (2)	KR102608590B1 (ja)
CN (1)	CN108064275A (ja)
AU (2)	AU2015320665B2 (ja)
CA (1)	CA2961748A1 (ja)
DK (1)	DK3198009T3 (ja)
ES (1)	ES2899913T3 (ja)
PL (1)	PL3198009T3 (ja)
WO (1)	WO2016049201A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2903582C (en)	2013-03-14	2021-06-08	Salk Institute For Biological Studies	Oncolytic adenovirus compositions
EP3198009B1 (en) *	2014-09-24	2021-09-08	Salk Institute for Biological Studies	Oncolytic tumor viruses and methods of use
AU2016333996B2 (en) *	2015-10-05	2020-05-28	Salk Institute For Biological Studies	Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
WO2017147265A1 (en)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	High throughput assay for measuring adenovirus replication kinetics
AU2017223589B2 (en) *	2016-02-23	2023-08-03	Salk Institute For Biological Studies	Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017375633C1 (en)	2016-12-12	2023-04-27	Salk Institute For Biological Studies	Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) *	2016-12-30	2018-07-05	Salk Institute For Biological Studies	Synthetic adenoviruses targeting bone tissue and uses thereof
BR112019015600A2 (pt) *	2017-01-30	2020-03-17	Epicentrx, Inc.	Múltiplos adenovírus recombinantes de transgene
EA201990822A1 (ru)	2017-04-12	2020-01-09	Эписентарикс, Инк.	Иммуномодулирующие слитые белки
US20210015878A1 (en) *	2018-03-28	2021-01-21	Epicentrx, Inc.	Personalized cancer vaccines
CN112292449A (zh) *	2018-04-09	2021-01-29	萨克生物研究学院	具有增强的复制特性的溶瘤腺病毒组合物
CN111363726A (zh) *	2018-12-26	2020-07-03	上海元宋生物技术有限公司	表达干扰素的溶瘤病毒及其应用
EP3927833A4 (en) *	2019-02-21	2022-11-30	Unleash Immuno Oncolytics, Inc.	ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
KR20220079551A (ko) *	2019-09-05	2022-06-13	클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨	종양 세포 붕괴성 아데노바이러스, cdk4/6 억제제 및 추가의 치료 활성제의 조합물에 의한 종양의 치료
EP3812465A1 (en) *	2019-10-21	2021-04-28	Universität Ulm	Adenovirus comprising a modified adenovirus hexon protein
JP2023513794A (ja) *	2020-02-14	2023-04-03	ソークインスティテュートフォーバイオロジカルスタディーズ	Ｕｌｋ１／２の阻害剤およびその使用方法
US20240247283A1 (en) *	2021-05-06	2024-07-25	Asimov Inc.	Compositions and methods for adeno-associated viral production

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030138405A1 (en)	2001-04-17	2003-07-24	Juan Fueyo	Conditionally replicative adenovirus to target the Rb and Rb-related pathways
ATE546531T1 (de) *	2003-12-31	2012-03-15	Kalobios Inc	Transaktivierungssystem für säugerzellen
US7473418B2 (en) *	2004-03-25	2009-01-06	Cell Genesys, Inc.	Pan cancer oncolytic vectors and methods of use thereof
CN103237889B (zh) *	2010-08-16	2017-04-05	萨克生物研究学院	腺病毒组装方法
CN104411826A (zh) *	2012-03-13	2015-03-11	萨克生物研究学院	使用腺病毒和化学二聚体的选择性细胞寻靶
CA2903582C (en) *	2013-03-14	2021-06-08	Salk Institute For Biological Studies	Oncolytic adenovirus compositions
CN111658670B (zh) *	2013-04-18	2024-10-01	蒂尔坦生物制药有限公司	溶瘤腺病毒载体与过继t细胞治疗组合物及其用途
EP3198009B1 (en) *	2014-09-24	2021-09-08	Salk Institute for Biological Studies	Oncolytic tumor viruses and methods of use

2015
- 2015-09-23 EP EP15843893.7A patent/EP3198009B1/en active Active
- 2015-09-23 EP EP21193392.4A patent/EP4043021A3/en active Pending
- 2015-09-23 AU AU2015320665A patent/AU2015320665B2/en active Active
- 2015-09-23 DK DK15843893.7T patent/DK3198009T3/da active
- 2015-09-23 JP JP2017515974A patent/JP6764859B2/ja active Active
- 2015-09-23 CA CA2961748A patent/CA2961748A1/en active Pending
- 2015-09-23 KR KR1020177011121A patent/KR102608590B1/ko active IP Right Grant
- 2015-09-23 ES ES15843893T patent/ES2899913T3/es active Active
- 2015-09-23 WO PCT/US2015/051745 patent/WO2016049201A1/en active Application Filing
- 2015-09-23 CN CN201580063723.9A patent/CN108064275A/zh active Pending
- 2015-09-23 KR KR1020237040919A patent/KR20230165385A/ko not_active Application Discontinuation
- 2015-09-23 PL PL15843893T patent/PL3198009T3/pl unknown
2017
- 2017-03-24 US US15/468,565 patent/US20170202893A1/en active Pending
2020
- 2020-09-14 JP JP2020153724A patent/JP7416423B2/ja active Active
2022
- 2022-05-24 AU AU2022203504A patent/AU2022203504A1/en active Pending
2023
- 2023-12-22 JP JP2023216375A patent/JP2024038030A/ja active Pending

Also Published As

Publication number	Publication date
KR102608590B1 (ko)	2023-12-01
JP7416423B2 (ja)	2024-01-17
CN108064275A (zh)	2018-05-22
KR20170063801A (ko)	2017-06-08
EP3198009B1 (en)	2021-09-08
AU2022203504A1 (en)	2022-06-09
EP4043021A2 (en)	2022-08-17
US20170202893A1 (en)	2017-07-20
EP4043021A3 (en)	2022-11-23
ES2899913T3 (es)	2022-03-15
WO2016049201A1 (en)	2016-03-31
JP6764859B2 (ja)	2020-10-07
KR20230165385A (ko)	2023-12-05
JP2017534263A (ja)	2017-11-24
EP3198009A1 (en)	2017-08-02
EP3198009A4 (en)	2018-09-05
DK3198009T3 (da)	2021-11-22
PL3198009T3 (pl)	2022-01-24
JP2021007392A (ja)	2021-01-28
AU2015320665B2 (en)	2022-06-16
AU2015320665A1 (en)	2017-04-06
JP2024038030A (ja)	2024-03-19

Publication	Publication Date	Title
AU2015320665B2 (en)	2022-06-16	Oncolytic tumor viruses and methods of use
AU2018322776B2 (en)	2023-04-06	Adenovirus armed with bispecific T cell engager (BiTE)
KR20160145825A (ko)	2016-12-20	알부민-결합 모이어티를 포함하는 아데노바이러스
WO2014201308A1 (en)	2014-12-18	Endothelial-targeted adenoviral vectors, methods and uses therefor
JP2011200234A (ja)	2011-10-13	新規アデノウイルス、それをコードする核酸及びその使用
JP2020504767A (ja)	2020-02-13	武装した複製可能な腫瘍溶解性アデノウイルス
CN112292449A (zh)	2021-01-29	具有增强的复制特性的溶瘤腺病毒组合物
JP5435871B2 (ja)	2014-03-05	Ｅ１−マイナスアデノウイルス及びその使用
JP2023014163A (ja)	2023-01-26	腫瘍を標的にする合成アデノウイルスおよびその使用
CN118308311A (zh)	2024-07-09	溶瘤病毒和方法
WO2006075165A1 (en)	2006-07-20	Combination of oncolytic viruses with angiogenesis inhibitors
JP2022521268A (ja)	2022-04-06	腫瘍溶解性アデノウイルスベクター及び使用法
WO2012022496A2 (en)	2012-02-23	Method for killing tumor stem cells
US20230220355A1 (en)	2023-07-13	Recombinant adenovirus genome having a synthetic transcriptional unit and two step transcriptional regulation and amplification
EA044599B1 (ru)	2023-09-13	Аденовирус, вооруженный биспецифическим активатором t-клеток
Van Geer	2011	Adenovirus targeting for gene therapy of pancreatic cancer
CA3188127A1 (en)	2022-01-13	Oncolytic adenovirus with replication selectivity based on status of p53 transcriptional activity
Fajardo Calderón	2017	Arming oncolytic adenoviruses with bi-specific T-cell engagers to improve antitumor efficacy
Young A	2012	Development of an immunocompetent model of oncolytic adenoviral gene therapy for ovarian cancer.

Legal Events

Date	Code	Title	Description
2020-09-25	EEER	Examination request	Effective date: 20200915
2022-09-16	EEER	Examination request	Effective date: 20200915
2022-09-20	EEER	Examination request	Effective date: 20200915
2023-02-17	EEER	Examination request	Effective date: 20200915
2023-03-09	EEER	Examination request	Effective date: 20200915
2023-09-11	EEER	Examination request	Effective date: 20200915
2023-10-14	EEER	Examination request	Effective date: 20200915
2024-02-09	EEER	Examination request	Effective date: 20200915